Invivoscribe Expands IVDR Portfolio with Certification of IdentiClone Dx IGH Assay Invivoscribe, a globally recognized leader in precision diagnostics and measurable residual disease (MRD) testing, has announced a major regulatory milestone with the successful certification of its IdentiClone Dx IGH…
Agenus to Host March 2026 Stakeholder Webcast Highlighting Progress of BOT + BAL Immunotherapy and Expanding Patient Access Across Multiple Tumor Types Agenus Inc., a biotechnology company focused on advancing innovative immuno-oncology therapies, has announced that it will host its…
Merck & Co., Inc. to Acquire Terns Pharmaceuticals, Inc., Strengthening Hematology Pipeline with TERN-701 for Chronic Myeloid Leukemia (CML) Merck & Co.—known as MSD outside the United States and Canada—and Terns Pharmaceuticals, Inc. have announced a definitive agreement under which…
Kallisio Secures CE Mark for Stentra™ Precision Oral Immobilization System Kallisio has announced a significant regulatory milestone with the CE certification of its innovative Stentra intraoral positioning system under the European Union’s Medical Device Regulation, EU MDR 2017 This certification…
FDA Clears Corcept’s Lifyorli™ (relacorilant) in Combination with Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer Treatment Corcept Therapeutics Incorporated has announced a major regulatory milestone with the approval of its novel therapy, Lifyorli™ (relacorilant), by the U.S. Food and Drug Administration. This…
Incyte Reports New Appointments to Its Executive Leadership Team Incyte has announced a series of key leadership appointments within its executive team, signaling a strategic move to strengthen its organizational structure and support long-term growth across research, development, and commercial…
Poxel Announces Drawdown of Additional Tranche D PDR Bonds Under Continuation Plan POXEL SA, a biopharmaceutical firm specializing in innovative therapies for serious chronic diseases with metabolic origins, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, has announced a…
Element Science Earns Spot on Fast Company’s 2026 List of the World’s Most Innovative Companies Element Science has earned a place on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026, a recognition that highlights organizations driving…
U.S. Food and Drug Administration Approves Updated Label to Enable Faster Thawing of ADSTILADRIN® (nadofaragene firadenovec-vncg) Ferring Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an important label update for ADSTILADRIN, introducing a faster and more…
Grifols Advances Plans to Launch IPO for Its U.S. Biopharma Division Grifols has taken a significant strategic step toward reshaping its corporate structure and accelerating long-term growth, as its Strategy Committee has proposed—and its Board of Directors has approved—the potential…
Alnylam Drives Innovation in ATTR-CM Care Through Strategic Collaboration with Viz.ai and Ongoing Support for the American Heart Association Alnylam Pharmaceuticals is spearheading a comprehensive, system-wide initiative aimed at transforming the early detection and management of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM),…
Dupixent Approved in Japan as the First Targeted Therapy for Adults with Bullous Pemphigoid Regeneron Pharmaceuticals and Sanofi have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Dupixent as a treatment for adults suffering…